Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue

被引：64
作者：
van Vollenhoven, Ronald F. [1 ]
机构：
[1] Karolinska Univ Hosp, S-17176 Stockholm, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷 / 07期
关键词：
D O I：
10.1136/ard.2007.069872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：849 / 851
页数：3
相关论文
共 26 条
  • [1] Ang HTS, 2003, J RHEUMATOL, V30, P2315
  • [2] BARTELDS GM, 2007, ANN RHEUM DIS
  • [3] Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
    Bendtzen, Klaus
    Geborek, Pierre
    Svenson, Morten
    Larsson, Lotta
    Kapetanovic, Meliha C.
    Saxne, Tore
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 3782 - 3789
  • [4] Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure
    Bennett, AN
    Peterson, P
    Zain, A
    Grumley, J
    Panayi, G
    Kirkham, B
    [J]. RHEUMATOLOGY, 2005, 44 (08) : 1026 - 1031
  • [5] Brocq O, 2002, PRESSE MED, V31, P1836
  • [6] True infliximab resistance in rheumatoid arthritis:: a role for lymphotoxin α?
    Buch, MH
    Conaghan, PG
    Quinn, MA
    Bingham, SJ
    Veale, D
    Emery, P
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) : 1344 - 1346
  • [7] Cohen G, 2005, CLIN EXP RHEUMATOL, V23, P795
  • [8] Delaunay C, 2005, J RHEUMATOL, V32, P2183
  • [9] Anti-tumor necrosis factor α switching in rheumatoid arthritis and juvenile chronic arthritis
    Favalli, EG
    Arreghini, M
    Arnoldi, C
    Panni, B
    Marchesoni, A
    Tosi, S
    Pontikaki, I
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (02): : 301 - 302
  • [10] Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
    Finckh, A.
    Simard, J. F.
    Gabay, C.
    Guerne, P. -A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) : 746 - 752
123